Caste politics rocks as BSY announces new office bearers of Karnataka BJP

Tumakuru, Jan 4: Three people were burnt alive and four others sustained injuries in a head-on collision between a four-wheeler (Omni van) and a private bus on NH-206 near Doddaguni in Gubbi taluk of Tumakuru district in the early hours of Saturday.

Police said that Narasamma’s relatives and villagers were taking her to a hospital in Nittur when a private bus, heading to Shivamogga from Bengaluru, collided with the van on the tank bund road near Doddguni around 0200 hrs. The two vehicles caught fire and Vasanthkumar, Ramaiah and Narasamma were burnt alive in the van. The passengers in the private bus escaped unhurt.

The deceased were identified as Vasanthkumar (23), Ramaiah (62) and Narsamma (60) of N Hosahalli in Gubbi taluk, whereas the injured were identified as Ravikumar (23), Radhamani (30), Narasimha Murthy (40) and Gowramma (28).

Bengaluru, May 5: A 62-year-old woman from Vijayapura succumbed to coronavirus infection on Tuesday, taking the COVID-19 death toll in Karnataka to 28, a health official said.

The state has registered eight more COVID-19 cases in the past 19 hours, increasing the count of such cases to 659, the official added.

"Positive case 640, 62-year-old female resident of Vijayapura died on Tuesday due to cardiac arrest," the health official said.

Admitted to a designated hospital''s ICU on Sunday, the woman was also suffering from Chronic Obstructive Pulmonary Disease (COPD), Bronchial Asthma (BA) and complained of breathlessness.

Among the eight fresh cases that emerged in the state, four were contacts of earlier cases, two with Influenza Like Illness (ILI) and one with travel history to Uttarakhand.

The health department is also tracing the contact history of a 30-year-old woman from Bengaluru Urban.

Incidentally, no new cases emerged from Davangere as 22 cases rocked the district on Monday.

Among the new cases, Bengaluru Urban contributed 3, followed by Bagalkote, 2, Ballari, Dakshina Kannada and Bhatkal in Uttara Kannada, 1 each.

Of the new cases, six are men and two women.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.